Genetic and Antigenic Variability of HIV Type 1 in Brazil

JOSÉ C. COUTO-FERNANDEZ,1 WOUTER JANSSSENS,2 LEO HEYNDRICKX,2 JAN MOTTE,2 KATRIEN FRANSEN,2 MARTINE PEETERS,2 ERIC DELAPORTE,3 BERNARDO GALVÃO-CASTRO,1 PETER PIOT,2 and GUIDO VAN DER GROEN2

ABSTRACT

Six Brazilian strains of human immunodeficiency virus type 1 (HIV-1) were isolated from infected individuals residing in different regions of Brazil between 1987 and 1989. Phylogenetic analysis based on an 860-base pair env fragment, including V3, V4, V5, and the beginning of gp41, classified the Brazilian strains significantly in genotype B, with interhost distances between 5.9 and 13.1% (mean value, 10%). Amino acid sequence analysis of the V3 loop revealed that three strains contained the North American/European GPGPR motif as the tip of the loop whereas in the other three strains proline (P) was substituted by tryptophan (W), methionine (M), or phenylalanine (F). A consensus peptide, Bra-cons, was designed containing GWGR as the tip of the loop. Serological reactivity to the Bra-cons peptide and other V3 peptides (MN, SF2, HBX2, RF, MAL, ELI, Z6, and a Côte d’Ivoire peptide, CI-cons) was compared for 114 HIV-1-positive sera from Rio de Janeiro. Sixty-nine sera (60.5%) reacted with peptides belonging to genotype B, of which 10 sera also reacted with peptides belonging to genotype A (n = 7) and D (n = 3). Eighteen sera (15.8%) had binding antibodies to the Bra-cons peptide. A high number of sera (n = 43; 37.7%) had no antibodies to any of the V3 peptides tested. This result suggests that HIV-1 variants with aberrant V3 loops may circulate in Rio de Janeiro.

INTRODUCTION

The envelope (Env) of HIV-1 contains highly variable regions. In the third variable region (V3) of the env gene, there are important determinants for virus neutralization,1,2 cell tropism,3,4 and viral infectivity.5 However, the role of distinct HIV variants in the development of AIDS is unclear. On the basis of the induction of neutralizing antibodies in experimental animals, this viral epitope is under investigation as a candidate for potential HIV-1 vaccines and as a target for immunoprophylaxis strategies.6 However, to protect against HIV infection it is important that vaccines should induce a protective immune response against a wide range of viruses, especially those most common within the community to be protected.

Brazil is one of the countries most affected by HIV-1. In November 1993, a cumulative total of 43,964 AIDS cases had been reported by the Ministry of Health for all 27 states.7 Data regarding HIV-1 diversity in Brazil has already established that subtype B viruses (some with unusual V3 sequences) are prevalent, with a smaller apparent proportion of subtype F viruses.8-13 The aim of the study was to analyze the genetic variability in the env gene of HIV-1 strains isolated from patients from different geographic regions in Brazil. Furthermore, we investigated the seroreactivity of 114 HIV-1 Western blot-confirmed seropositive Brazilian individuals to peptides mimicking the principal neutralizing domain (PND) of the V3 loop of HIV-1 strains belonging to different genotypes as well as to a consensus PND peptide of Brazilian isolates.

MATERIALS AND METHODS

Subjects

HIV-1 strains of six HIV-1-infected individuals residing in different regions in Brazil and attending public hospitals during the time period between 1987 and 1989 were included in this study. The CD4+ cell counts (× 10⁹/liter), the most widely used marker for staging of asymptomatic HIV infection,14 are indicated: F3 (CD4 < 200), São Paulo; P4 (200 < CD4 < 500), P6 (200 < CD4 < 500), and P7 (CD4 > 500), Bahia; P8 (200 < CD4

1Advanced Public Health Laboratory, Centro de Pesquisas Gonçalo, Fundação Oswaldo Cruz, Bahia CEP 41-945, Brazil.
2Division of Microbiology, Department of Infection and Immunity, Institute of Tropical Medicine, 2000 Antwerp, Belgium.
3INSERM U13/IMEA-Hôpital Bichat-Claude Bernard, Paris, France.
Peptides

The V3 synthetic peptides were 20 to 22 amino acids long and contained a cysteine residue at the amino terminus for binding purposes in the enzyme-linked immunosorbent assay (ELISA). The peptides cover the PND and are derived from sequences from genotype A (Cl-cons: Côte d’Ivoire), genotype B (MN, SF2, and HBX2, North America; RF, Haiti; Bra-cons, Brazil) and genotype D (ELI, Z6, and MAL, Zaire). Genotype classification was according to Myers et al.16 The alignment of the V3 peptides is shown in Fig. 1. Amino acid numbering is according to the MN strain.16 The peptides were synthesized at Neosystems (Strasbourg, France). The Cl-cons peptide was designed on the most common V3 sequences of Côte d’Ivoire strains as previously described.17 The Bra-cons peptide was designed on V3 loop sequences of this study and sequences from HIV-1 strains from Bahia and São Paulo9 and Rio de Janeiro.10,11 A consensus sequence was derived in which proline (P) in the central GPR motif was exchanged for tryptophan (W), resulting in the peptide cNTRKSHIGWGRAFYATGE.

Peptide assay

An ELISA was used to monitor antibody reactivity to the V3 loop peptides. Stock solutions (1 mg/ml) of these peptides were reconstituted in 0.05 M carbonate buffer (pH 9.6) and stored at -20°C. Peptides, at a concentration of 100 ng/200 μl of carbon-

ate buffer, were coated overnight at room temperature in microtiter plates (Immunoplate; Nunc, Roskilde, Denmark). The plates were washed twice with phosphate-buffered saline (PBS)-0.01% merthiolate-0.05% Tween 20. Nonspecific binding sites were blocked with blocking buffer (PBS-0.05% Tween 20–2% bovine serum albumin) at 37°C for 2 hr. Of serum dilutions, made in blocking buffer, 200 μl was incubated with the immobilized peptides for 1 hr at 37°C. The plates were washed and incubated with blocking buffer containing anti-human IgG-peroxidase conjugate, diluted 1:30,000, for 1 hr at 37°C. The plates were washed and antibody binding was visualized by adding substrate buffer (8.7 mg of tetramethylbenzidine/ml dimethyl sulfoxide [DMSO] diluted 1:100 in 0.1 M citrate phosphate buffer, pH 4.3, and 0.006% H2O2). After 30 min the reaction was stopped by adding 50 μl of 4 N H2SO4. The optical density was read at 450 nm. Ten HIV-1-negative sera were used to establish the cutoff value of each assay as the mean value plus 3 standard deviations. Antibody reaction to a peptide was scored positive if the optical density (OD) value was above the cutoff value. Cutoff values ranged from 0.1 to 0.5. For uniformity and to eliminate nonspecific reactivity the highest cutoff value (0.5) was used for all the assays.

Virus isolation and DNA preparation

HIV-1 isolation was carried out according to Barré-Sinoussi et al.18 Briefly, 2 x 105 periferal blood mononuclear cells (PBMCs) from HIV-1-seropositive individuals were separated on a Ficoll-Hypaque gradient and cocultivated with 5 x 106 phytohemagglutinin (PHA)-stimulated donor PBMCs. The cultures were maintained in RPMI-1640 medium supplemented with 20% heat-inactivated fetal bovine serum and recombinant interleukin 2 (20 U/ml) (Innogenetics, Zwijnaarde, Belgium). Cultures were expanded to 2.5 x 106 cells by adding 2 x 106 PHA-stimulated donor PBMCs every 3 to 4 days over a 2- to 3-week period. Viral growth was determined by monitoring viral antigens by an HIV antigen capture enzyme immunoassay (EIA; Innogenetics). HIV-containing supernatants were kept at -70°C until use. Frozen infected cells were thawed and resuspended in 1 ml of TE buffer (10 mM Tris-HCl pH 7.5); 1 mM ethylenediaminetetraacetic acid (EDTA) and treated with 0.5% sodium dodecyl sulfate (SDS) and proteinase K (20 μg/ml) at 37°C overnight. Nucleic acids were extracted by phenol–chloroform,19 precipitated in absolute ethanol, and resuspended in 100 μl of H2O. The quantity of total DNA was measured by optical density and their concentration adjusted to a final concentration of 0.1 μg/ml.

Polymerase Chain Reaction, cloning, and sequencing

The polymerase chain reaction (PCR) conditions and primers were as described previously.17 Primer H1E101 was biotinylated for direct sequencing purposes. An approximately 860-base pair (bp) fragment containing V3, V4, V5, and the beginning of gp41 was amplified for the six Brazilian strains. Nested PCR fragments were purified with Dynabeads (Medichem, Heppgnies, Belgium) and directly sequenced using the direct solid-phase sequencing approach.28 For one isolate (P6) it was not possible to obtain a satisfactory nested PCR product. This fragment was cloned in a pUC18 cloning vector. Sequence reactions were performed using the AutoRead se-
HIV-1 STRAINS IN BRAZIL

Sequencing kit and fluorescein-labeled primers (Pharmacia Biotech, Roosendaal, the Netherlands). Electrophoresis and data collection were done on an ALF automatic sequencer (Pharmacia Biotech).

Sequence data analysis

The six HIV-1 env Brazilian sequences were aligned with 19 previously known sequences of HIV-1 isolates of diverse geographical origin. Starting from the alignment, a distance matrix, corrected for multiple mutations per site according to Jukes and Cantor,21 was constructed.22 Tree topologies were inferred by neighbor joining,23 one of the most effective tree construction methods available at this time.24,25 Tree construction and bootstrap analysis were realized with the software package TREECON.26

The nucleotide sequence data were deposited in the EMBL, GenBank, and DDBJ nucleotide Sequence Database under the following accession numbers: X78512–X78517.

RESULTS

Phylogenetic analysis

The Brazilian sequences were compared phylogenetically with the 860-bp env fragment of 19 previously published sequences representative of 6 different genotypes: 4 strains of genotype A (Z321 [Zaire], D687 [Ghana], SF170 [Rwanda], and U455 [Uganda]), 5 strains of genotype B (OY1 [Gabon], LAI [France], RF [Haiti], and MN and SF2 [United States]), 2 strains of genotype C (NOF [South Africa] and D747 [India]), 4 strains of genotype D (NDK, JY1, Z2Z6, and ELI [Zaire]), 2 strains from genotype E (CM235 and CM239),27 and 2 strains from genotype F (BZ126 and BZ163).13 SIVcpz=Gab was included as outgroup sequence.

In the phylogenetic tree (Fig. 2), six branches representing six different genotypes (A, B, C, D, E, and F) are supported significantly by bootstrap analysis. All Brazilian isolates in this study are situated in genotype B, supported by 100% of the bootstrap trees. The interhost differences at nucleotide level for Brazilian strains were 5.9% (between P3 and P6) to 13.1% (between P8 and P9). The mean value for interhost difference was 10%.

Genetic analysis of the V3 region

V3 amino acid sequences from Brazilian isolates were compared with the V3 consensus sequence of genotype B (Fig. 3).16 The amino acid sequences around the V3 loop apices were similar to those of some North American and European isolates. The central GPGR tetrapeptide was found in three of six Brazilian strains. In the other three samples (P3, P6, and P8), proline (P) in the crown of the loop was replaced by tryptophan (W), methionine (M), and phenylalanine (F), respectively.

![FIG. 2. Phylogenetic tree based on 853 unambiguously aligned positions of HIV-1 sequences from 25 different patients. The sequences determined in this study are indicated in bold. The root of the tree is placed such as to equalize its distance to the outgroup sequence SIVcpz=Gab and its average to the HIV-1 sequences. The distance between two sequences is obtained by summing the lengths of the connecting horizontal branches, using the scale on top. The number of bootstrap trees out of 1000 replications supporting a particular phylogenetic group in more than 50% is placed alongside the node considered.](image-url)
Antibody reactivity of sera from HIV-seropositive Brazilian individuals against V3 loop peptides in ELISA

Eighteen different seroreactivity patterns have been observed among the 114 Brazilian HIV-1-positive sera when tested in ELISA on 9 different V3 peptides (Fig. 4A). Of the 114 HIV-1-positive sera from Rio de Janeiro tested, 69 (60.5%) reacted to 1 or more peptides mimicking V3 loop sequences of HIV-1 strains classified in genotype B (Figs. 1 and 4A). Seven of these sera also reacted with the CI-cons peptide (genotype A); two sera also reacted with the Z6 peptide and one serum also reacted with the ELI and MAL peptides (genotype D). The number of sera having antibody reactivity to the RF and HBX2 peptides was 14 (12.3%) and 8 (7%), respectively. All sera reacting to the RF and/or the HBX2 peptide also reacted to the SF2 and MN peptides. All but one of the sera having antibodies to the SF2 peptide (n = 39) also reacted to the MN peptide (n = 38). Of 18 sera (15.8%) that reacted with the Bra-cons peptide, 2 did not cross-react with other V3 peptides. Three sera had serological reactivity to V3 peptides based on Zairean HIV-1 strains, classified in genotype D; two sera reacted with the Z6 peptide and one serum reacted with the ELI and MAL peptides.

Nine sera (7.9%) had antibodies directed to the CI-cons peptide. Two of these sera did not react with other peptides. Forty-three sera (37.7%) had no binding antibodies directed to epitopes on the V3 peptides used in this study (Fig. 4A). An increase in the cutoff value from OD = 0.5 to OD = 1.0 resulted in a decrease in the number of sera reacting with a certain V3 peptide in ELISA (Fig. 4B). The number of different seroreactivity patterns was now reduced to 12. The percentage of sera having antibody reactivity to one or more V3 peptides decreased by 28% (from n = 71 to n = 51). All of them had antibodies to subtype B peptides. The decrease in reactivity toward the different V3 peptides was as follows: 29% for the MN peptide (from n = 66 to n = 47), 36% for the SF2 peptide (from n = 39 to n = 25), 43% for the RF peptide (from n = 14 to n = 8),

FIG. 3. Amino acid sequence alignment of part of the envelope glycoprotein, including V3, V4, V5, and the beginning of gp120 of six Brazilian strains. The database consensus sequence for genotype B, according to Myers et al., is on top. Amino acid identity between sequences is represented by points; dashes are introduced to align the sequences; the overbars are indicative for the V3 loop region and the CD4 binding site as indicated between them.

FIG. 4. Antibody reactivity of Brazilian sera to V3 loop peptides of HIV-1 isolates of different genotypes. The inside of each ellipse, indicated by a reference peptide, contains the number of sera reactive with this peptide. The genotypes of the strains from which the V3 loop peptides are derived are indicated in parentheses. A separate ellipse contains the number of sera having no binding antibodies to the V3 peptides tested. (A) Cutoff OD = 0.5; (B) cutoff OD = 1.0.

COUTO-FERNANDEZ ET AL.
Antibody reactivity to the Bra-cons peptide

Antibody reaction to the Bra-cons peptide was studied for sera from Belgium (n = 139), Rwanda (n = 207), Gabon (n = 90), and Kenya (n = 60), and compared to antibody reaction for sera from Brazil (n = 114). The percentage of sera from the different countries, scoring positive (OD > 0.5) in the peptide assay, was 15.8% (n = 18) for Brazil, 7.2% (n = 10) for Belgium, 6.8% (n = 14) for Rwanda, 4.4% (n = 4) for Gabon, and 6.7% (n = 4) for Kenya. To determine the specificity of antibody reaction to the Bra-cons peptide, the OD values of the sera from the different countries reacting with this peptide were compared (Fig. 5). An increase in the cutoff value from OD = 0.5 to OD = 1.0 resulted in a decrease in the number of sera scoring positive in ELISA: in Brazil, 11% (from n = 18 to n = 16); in Belgium, 60% (from n = 10 to n = 4); in Rwanda, 64% (from n = 14 to n = 5); in Gabon, 100% (from n = 4 to n = 0); and in Kenya, 100% (from n = 4 to n = 0).

**DISCUSSION**

Using the env fragment encoding V3, V4, V5, and the beginning of gp41, it is possible to generate phylogenetic trees that are statistically confident and that group HIV-1 strains into the same genotypes as documented by Myers et al., based on larger fragments or total genomes. All Brazilian strains in this study clustered in genotype B. The GPGR motif was present in 50% of the Brazilian strains (P4, P7, and P9). The Brazilian strains lacking GPGR had GWGR (P3, São Paulo), GMGR (P6, Bahia), and GFGGR (P8, Paraná) instead. Globally, GPGR is found in B subtypes only 63% of the time. In the Centers for Disease Control (CDC, Atlanta, GA) study of a Florida dentist, out of 39 Florida control strains 12 did not have GPGR as the tip of the V3 loop. In a seroconverter study from the Netherlands, 11 of 75 strains were variable in GPGR. Finally, it is not uncommon to find intrapatient variation in this motif, which has implications for serological reactivity. V3 sequence data from HIV-1 strains circulating in Bahia and São Paulo, Brazil, were reported. Thirty-six percent (n = 8) of the strains had the GWGR tetrapeptide motif and were from individuals from Bahia. Also, V3 sequence data from HIV-1 strains circulating in Rio de Janeiro and São Paulo were reported. Forty-three percent (n = 12) of the strains had the GWGR tetrapeptide motif, GPGR was observed in only eight strains (28.5%), and eight strains (28.5%) presented a novel sequence. The GWGR tip of the loop has been found only in Brazil to date. It is a common form in Brazil, and its presence accounts for much of the decrease in frequency of GPGR forms in Brazil. Therefore the relative decrease in GPGR could be due to a founder effect with the GWGR form, and not to the excessive variation in this motif in Brazil. A study on 30 samples from patients of Argentina revealed only GPG as the tip of the V3 loop. This may be due to a recent introduction or to clustering of the samples in that study. The prevalence of HIV-1 strains having GWG, GMG, or GFG as the tip of the V3 loop, for other regions of Brazil and for other South American countries, remains unclear. Although the majority of Brazilian isolates belong to genotype B, the presence of genotype F isolates has been demonstrated.

The prevalence of antibodies binding with the Bra-cons peptide, having GWG as its central motif, was studied for 114 HIV-1-positive Western blot-confirmed sera from Rio de Janeiro and compared with the seroreactivity to other peptides of HIV-1 strains from different geographic regions. Seventy-one sera

---

**FIG. 5.** Specificity of antibody reaction to the Bra-cons peptide. The percentage of sera of the different countries reacting with the Bra-cons peptide is indicated in order of increasing OD values.
(62.3%) had serological activity to one or more V3 peptides in this study. All except two had binding antibodies to V3 peptide(s) based on genotype B sequences. This finding corresponds with the phylogenetic classification in genotype B of the HIV-1 strains from Brazil in this and previous studies. However, a prevalence of 60% of MN V3 peptide-reactive Brazilian sera was low compared with the prevalence of MN V3 peptide-reactive sera observed in eight other countries, of which one was European and seven were African. This observation, together with the low number of sera reacting with peptides of genotype D strains, made Brazilian seropositive sera different in their V3 loop reactivity pattern (data not shown). Antibody reaction of Brazilian sera to the Bra-cons peptide was 15.8%. Brazilian sera reacted with higher specificity to the Bracons peptide in comparison with sera from Belgium, Rwanda, Gabon, and Kenya (Fig. 5). Raising the cutoff value from OD = 0.5 up to OD = 1.0 resulted in an increased specificity and eliminated some of the cross-reactivity against the Bra-cons peptide. This is reflected by an 11% (Brazil) versus a 60% (Belgium), 64% (Rwanda), and 100% (Gabon and Kenya) reduction in the number of sera reactive with the Bra-cons peptide, in solid-phase ELISA. Antibody reaction of Brazilian sera to the C1cons peptide (genotype A) was low (7.9%), compared to sera from seven African countries ranging from 70.7% (Gabon) to 94.7% (Côte d'Ivoire) (data not shown). This may indicate a different evolution of HIV-1 strains in Africa and Brazil. Raising the cutoff value from OD = 0.5 to OD = 1.0 resulted in a decrease in Brazilian sera having antibodies to certain V3 peptides. The decrease was different for each V3 peptide analyzed. The lowest decrease was observed for reaction with the Bra-cons peptide (11%). The decrease in reactivity to other genotype B-derived peptides was more profound: MN, 29%; SF2, 36%; RF, 43%; and HBX2, 75%.

The high number of sera (n = 43; 37.7%) having no binding antibodies to any of the V3 peptides tested may indicate the presence of V3 loop-aborrent HIV-1 strains in Brazil, as is partially confirmed by our results. Although the six Brazilian isolates all belong to clade B, 50% of them had a remarkable difference at the tip of the loop (F3 [GWGR], P6 [GMRG], and P8 [GFGR]). Perhaps some of the nonreacting sera could react with a subtype F V3 peptide containing a relatively distinctive LGPG(Q/R). Also, the lack of reactivity of many of the sera could be due to positions proximal to the tip of the V3 loop. Serotyping using peptides corresponding to new variants may be important to trace the prevalence of these variants in the population. The PND present on the synthetic peptides contains a core tetrapeptide in a β-turn array that is highly conserved as GPGR for North American/European strains and as GPGQ for African strains. However, the PND of Brazilian strains often shows substitution of proline (P) in the GPG motif to tryptophan (W), methionine (M), and phenylalanine (F). This kind of substitution may result in an altered epitope eliciting antibodies with low or no binding affinity for V3 peptides having GPGR or GPGQ as the tip of the V3 loop. These data are indirect evidence for the circulation in Brazil of HIV strains with aberrant V3 loop amino acid sequences. Further work is necessary to characterize in further detail these unusual HIV-1 strains as well as to determine their prevalence among Brazilian HIV-infected individuals. The outcome of these studies may contribute to a more efficient design of an HIV vaccine in Brazil.

ACKNOWLEDGMENTS

The authors thank Betty Willems and Annemie Leenaers for technical assistance. They gratefully acknowledge the following people for providing sera for this study: Dr. B. Colebunders, Dr. M. Vandenbruene, and Dr. J. Goeman (Belgium), Dr. J. Bogaerts (Rwanda), Dr. L. Perret (Gabon), and Dr. M. Temmerman (Kenya). This work was supported by grants (Nos. 3-3025-91 and F5/525-RN-N24) from the National Funds voor Wetenschappelijk Onderzoek (Brussels) and was partially supported by the Brazilian National Research Council (CNPq-RHAE).

REFERENCES

13. Louwagie J, Delwart EL, Mullins JI, McCutchan FE, Eddy G, and Burke DS: Genetic analysis of HIV-1 isolates from Brazil reveals

Address reprint requests to:
Wouter Janssens
Division of Microbiology
Department of Infection and Immunity
Institute of Tropical Medicine
Nationaalstraat 155
2000 Antwerp, Belgium
This article has been cited by:

1. Adriana de Brito, Shirley C. V. Komninakis, Patricia Novoa, Rafael M. de Oliveira, Luiz Augusto M. Fonseca, Alberto J. S. Duarte, Jorge Casseb. 2006. Women Infected with HIV Type 1 Brazilian Variant, Subtype B (B'-GWGR Motif) Have Slower Progression to AIDS, Compared with Patients Infected with Subtype B (B-GPGR Motif). *Clinical Infectious Diseases* **43**:11, 1476-1481. [CrossRef]


3. MOHAMMED ABID, CHI-CHENG LUO, SOUAD SEKKAT, NICK DE LATORE, HALIMA MANSOUR, DEBRA HOLLOMAN-CANDAL, MARK RAYFIELD, ABDELLAH BENSILIMANE. 1998. Short Communication: Characterization of the V3 Region of HIV Type 1 Isolates from MoroccoShort Communication: Characterization of the V3 Region of HIV Type 1 Isolates from Morocco. *AIDS Research and Human Retroviruses* **14**:15, 1387-1389. [Citation] [PDF] [PDF Plus]


5. June E. Osborn. 1995. HIV: The more things change, the more they stay the same. *Nature Medicine* **1**:10, 991-993. [CrossRef]

6. AGUEDA CABELLO, MARGARITA CABRAL, MARIA ELISA VERA, RENATE KIEFER, RICARDO MORENO AZORERO, JOSEF EBERLE, LUTZ GÜRTLER, ALBRECHT VON BRUNN. 1995. Analysis of the V3 Loop Sequences from 10 HIV Type 1-Infected AIDS Patients from ParaguayAnalysis of the V3 Loop Sequences from 10 HIV Type 1-Infected AIDS Patients from Paraguay. *AIDS Research and Human Retroviruses* **11**:9, 1135-1137. [Citation] [PDF] [PDF Plus]